drugset / Trial / NCT00322972

Trachoma Amelioration in Northern Amhara (TANA)

NCT00322972

Phase 4 Completed 33000 enrolled University of California, San Francisco
RandomizedParallel-groupSingle-blindTreatment

Summary

The WHO has initiated a program to eliminate trachoma, blinding eye infection caused by Chlamydia trachomatis, in large part by mass distributions of oral azithromycin. The proposed study will determine the frequency and treatment target of community-wide mass antibiotic treatment. We will also study the impact of mass antibiotic distribution on antibiotic-resistance in pneumococcus.

Timeline

Start
2006-06
Primary completion
2009-11
Completion
2014-05

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule Oral

Indications